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bstract
The aim of this review was to assess cancer pain management in children on the basis of research published in the last ten years. Nine
ere papers providing clinical data, with a minimum of ten patients. No controlled studies were found. Regardless of general principles and
xisting recommendations, clinical data should confirm the applicability of this concept. The trials published in the last years did not provide
urther information to improve cancer pain management in children, because of the experience and the low number of drugs used, reflecting
nly meaningful opinions of experts in the field. The amount and the quality of data still remain poor, as only 737 subjects (about 80 patients
er year) were surveyed with open-label designs or retrospective analysis. No comparison among possible treatments or drugs has ever been
erformed. Most of these trials are short-lived and assessment of adverse effects is often problematic. The experience with opioids is quite
imited, and adjuvants have been seldom assessed, unless for case reports which have not been considered in this analysis. The management
f breakthrough pain has never been specifically evaluated.Further clinical trials are needed to evaluate dose equivalence, clinical efficacy and safety of opioid analgesics, differences in opioid
esponse, adjuvants and other drugs commonly used to manage opioid-related adverse effects, and dose strengths necessary for most children.
 2014 Elsevier Ireland Ltd. All rights reserved.
eeywords: Cancer pain; Children; Pediatrics; Opioids
.  IntroductionPain in a child with cancer poses significant challenges for
ealth professionals. Pain is the most common discomfort
∗ Corresponding author at: Anesthesia & Intensive Care and Pain Relief &
upportive Care Unit, La Maddalena Cancer Center, Via San Lorenzo 312,
0146 Palermo, Italy. Tel.: +39 0916806521; fax: +39 0916806110.
E-mail addresses: terapiadeldolore@lamaddalenanet.it,
3sebelle@gmail.com (S. Mercadante).
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ttp://dx.doi.org/10.1016/j.critrevonc.2014.01.005xperienced by children with cancer and occurs in almost
9% of patients in an advanced stage of the disease. It is
ost often not adequately treated because of inexperience and
nfounded fears of analgesic treatment [1]. About ten years
go an analysis of scientific literature regarding cancer pain
anagement in children evidenced that existing data were
imited and that most recommendations were substantially
rovided on the basis of anecdotal experience translated by
tudies in adults [2]. The aim of this review was to assess
ancer pain management in children on the basis of research
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ublished in the subsequent years to appreciate whether more
onsistent data have been produced to provide more robust
ata in this population.
.  Research  methods
A systematic search of the existing literature from 2004
o December 2013 was performed via electronic database
ubMed (http://www.ncbi.nlm.nih.gov) (filter 10 years). The
erms were “cancer pain” AND “children” OR “pediatrics”.
eferences contained in the article finally selected were
eviewed as to the possibility of finding any additional papers
f interest. Browsers of pediatric journals were also assessed.
or those articles in which the title and/or abstract were not
vailable or were insufficient to clarify the content of the arti-
le, the article was read in its entirety to make the decision
ver its content by the two authors. To be included in this
ystematic review, papers had to be full text clinical reports
tudying the pharmacological management of cancer pain
n children and published in English language. All clinical
tudy designs were eligible, but case-series with less than
0 patients were not considered. Papers assessing procedural
ain and treatment-induced pain were excluded. Non-clinical
eports such as reviews were also excluded.
.  Results
The initial search resulted in 61 hits. Title, abstracts or
hen necessary the full text paper were screened for inclu-
ion. Eight papers met the inclusion criteria. Other five papers
ere found after checking cross-references or consulting the
rincipal journals of the field (pediatrics, pain, and palliative
are). Globally 13 papers in the period taken into consid-
ration provided new clinical data with a minimum of ten
atients.
No controlled studies were found. Details of the clinical
apers examined are shown in Table 1. Globally, 935 children
ere surveyed. In six studies [3–8], 706 subjects were treated
ccording the WHO ladder, most of them successfully, with
imited and acceptable adverse effects.
Specific drugs have been assessed. In one study transder-
al buprenorphine was found to represent an efficient, safe
nd well tolerated approach to the management of children’s
hronic cancer pain. Eleven patients (68.75%) responded
o transdermal buprenorphine after 2 weeks of treatment.
ain intensity and all outcome measures of global quality
f life, including quality of sleep, alimentation, play and
ctivity, speech, and crying significantly improved over the
0-day study period. No severe adverse events were recorded
9]. Good analgesia with high level of satisfaction has been
eported in 18 children treated with fentanyl given as patient-
ontrolled analgesia. All children experienced a good degree
f analgesia and did not require any other analgesic drug dur-
ng the treatment. Both subjective and objective parameters
mproved after starting pain-relieving treatment and no major
c
c
p
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ide effects occurred [10]. In a multicenter study, transdermal
entanyl was found to be a safe and well tolerated alternative
o oral opioid treatment. 132 cancer children from a sample
f 173 with chronic pain who were previously exposed to
pioid therapy were switched to transdermal fentanyl. Pain
ntensity scores and quality of life items improved, although
bout 80% of patients discontinued the treatment for a vari-
ty of reasons. The treatment for well-tolerated and serious
dverse effects was reported in 9.5% of patients [11].
Two retrospective studies assessed the effects of opi-
id switching. In a series of seventeen patients switched to
ethadone, there was an improvement in analgesia with 16
atients remaining on methadone therapy until death for a
edian of 36 days [12]. Twenty-two children (14%) on opioid
herapy underwent 30 opioid rotations. The opioid was substi-
uted either for excessive side effects or inadequate analgesia.
ive patients (23%) required two rotations, 3 during the same
dmission. Adverse opioid effects improved in 90% of cases,
nd all failures occurred when morphine was rotated to fen-
anyl. There was no significant loss of pain control or increase
n mean morphine equivalent dose requirements [13].
One series reported about the effectiveness of ketamine in
hildren receiving high doses of opioids. Subanesthetic doses
f ketamine were used to treat 11 children who were on high
oses of opioids and had uncontrolled cancer pain. In 8 of 11
atients, ketamine appeared to improve pain control and to
ave an opioid-sparing effect [14].
Data regarding interventional procedures were limited.
ne retrospective analysis of a small series assessed the use
f epidural and peripheral nerve blocks in very advanced can-
er children. Pain scores improved in nine cases in 1–5 days.
 continuous catheter-delivered pain blockade contributed
o analgesia, moderated opioid requirements, and did not
reclude death at home [15].
.  Discussion
Despite increasing awareness about causes and treatment
f pain in children, most of them with advanced illness still
xperience pain and receive suboptimal pain control [1].
he World Health Organization documents on cancer pain
elief and palliative care in children has advocated the global
pplication of the principles of pain management and pal-
iative care for children with cancer. The principles of pain
anagement include the application of the WHO analgesic
adder, appropriate opioid dose escalation, the use of adjuvant
nalgesics, and the use of non-pharmacological methods of
ain control. These principles of pain management should be
ncorporated into the treatment protocols of all children with
ancer, acknowledging that treatment options may be limited
or some children [16]. However, regardless of general prin-
iples, clinical data should confirm the applicability of this
oncept and should suggest more specific recommendations
articularly in more complex categories. At the moment there
s no scientific evidence regarding the strategies to be used for
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Table 1
Trials on pharmacological management of cancer pain in children.
Authors No patients Setting Duration days Drug and dose Analgesic response Notes Tolerability
Ruggiero et al. (2013) 16 Cancer pain 60 Transdermal
buprenorphine
8.75–35 g/h
81.3% Better quality of
sleep, alimentation,
play and activity,
speech, and crying
Good 93.8% Low
tolerance
Geeta et al. (2010) 39 Acute
leukemia
NA WHO ladder 31% on step 1
54% on step 2
15% on step 3
Step 3 analgesia in
neuropathic and bone
pain.
Constipation
Anghelescu et al. (2010) 14
retrospective
Cancer pain 3–81 11 epidural
3 nerve blocks
12/13 evaluable
blocks improved pain
control
No preclusion of
death at home
None
Mishra et al. (2009) 84 Cancer pain 3 weeks WHO ladder Relevant decrease of
pain intensity,
independently of pain
mechanism
82% on step 3 after
three weeks
Acceptable number of
adverse effects
Hewitt et al. (2008) 185
prospective
Cancer pain Until death WHO ladder NA Strong opioids 89%,
Morphine 75%
Mean doses
6.1–29.5 mg/kg
Higher doses with
solid tumors
Nausea
Davies et al. (2008) 17
retrospective
Cancer pain Until death
Median 36
days
Switched to
methadone
Better pain control
(94% by parents)
Starting dose
0.1 mg/kg
Zhen et al. (2007) 139 Cancer pain NA WHO ladder 92.8% complete relief 74.8% on step 1
25.2% changing steps
No severe adverse
events
Ruggiero et al. (2007) 18 Cancer pain 48 h Transdermal fentanyl
1 g/kg/h
PCA 1 g/kg
Good degree of
analgesia
High grade of
satisfaction
No major adverse
effects
Finkel et al. (2007) 11 Cancer pain 1–75 days Ketamine
0.1–1 mg/kg/h
8/11 patients had a
good response
Opioid sparing effect No psychotropic
adverse effects
Zernikov et al. (2006) 124 Mostly pain
due to
treatment
2265
treatment days
WHO ladder Effective analgesia
with opioids
The mean intravenous
morphine equivalence
dose was
0.034 mg/kg/h.
Adverse effects were
more frequent
Finkel et al. (2005) 132
prospective
Cancer pain
mostly
leukemia
15 days Converted from
morphine to
transdermal fentanyl
86% effective
analgesia
Reduction of rescue
medications
0.98 g/h/kg to
1.2 g/h/kg data
mixed with
non-cancer population
3% withdrawal for
adverse effects
Monteiro-Caran et al. (2005) 135 Cancer pain Mean 34 days WHO ladder
Strong opioids 23%
Satisfactory pain
control in 97% of
cases
Initial dose of oral
morphine 1.8 mg/kg,
final dose 7 mg/kg
74% adverse effects
Psychological
dependence in 2% of
patients
Drake et al. (2004) 21 pts Mucositis 70% NA Opioid switching,
prevalently from
morphine to fentanyl
No loss of analgesia,
without increasing
opioid doses
Adverse effects
resolved in 90% of
cases
Adverse effects
resolved in 90% of
cases
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ancer pain management and recommendations are provided
n limited experience, with limited number of drugs, reflect-
ng only meaningful opinions of experts in the field. About
en years after a review on the management of cancer pain in
hildren [2], the amount and the quality of data still remain
oor, as less than 1000 thousand subjects (about 90 patients
er year) were surveyed with open-label designs or retrospec-
ive analysis. Other than generic recommendations of WHO
adder, as in adults, it is likely that an individualized treat-
ent may improve the outcome or reduce adverse affects. Of
nterest, no comparison among possible treatments or drugs
as ever been done. Most of these trials are short-lived, or
he duration of treatment not clearly explained, and assess-
ent of adverse effects is often problematic. The experience
ith opioids is quite limited, and adjuvants have been seldom
ssessed, unless for case reports which have not been con-
idered in this analysis. The management of breakthrough
ain has never been specifically evaluated and only a study
ssessed the characteristics of this phenomenon in a small
umber of patients [17].
Other than the limited evidence of the existing recom-
endations, several practical points remain unclear and have
linical implications, due to unavailability of some prepara-
ions. For example, in pediatric hematology/oncology, pain
ontrol by oral long-acting morphine proved to be safe
nd effective even in the very young patients. The phar-
acological properties of long-acting morphine are ideally
uited for pediatric use, combining efficacy and compatibil-
ty [13], and initial doses of opioids have been suggested,
ased on the weight of children [11]. However, commercial
reparations do not often fit the dose flexibility of opi-
ids requested for children, particularly with slow release
reparations or transdermal drugs. Only oral methadone and
orphine can be provided as immediate release preparations
hich can be graduated in a syrup preparation, according
o the weight. Alternately, parenteral morphine can be pro-
ided in precise doses. Similarly, transdermal opioids have
een often reported as effective and non-invasive method for
rug administration in children since it avoids discomfort due
o intravascular or oral administration. Transdermal opioids
epresent a useful alternative, because low doses can be tail-
red according the needs just cutting the new matrix patch,
s in most countries low dose strengths are unavailable [10].
Opioid switching may have a positive impact on managing
ose-limiting side effects of, or tolerance to, opioid therapy
uring cancer pain treatment in children. In small retrospec-
ive series, this was accomplished without loss of pain control
r having to significantly increase the dose of opioid therapy.
espite these encouraging data, this therapeutical approach
emains limited to experienced people, due to the lack of
rospective data.
Treatments alternative to opioids may be helpful in
ome circumstances of difficult pain. There are a number
f small case series that suggest that ketamine is a useful
edication for the control of chronic pain in children. To
ate, however, there are few data that aid a pediatrician
Rn Oncology/Hematology 91 (2014) 93–97
n determining if ketamine is a safe and effective option
or children with cancer pain, whose brains are immature
nd whose metabolism is different from that of adults [18].
inally, data on invasive procedures remain anecdotal, and
recise indications on who should receive such treatments,
hen these should be performed, and how these should be
dministered remain unclear.
.  Conclusion
The effective management of pain in pediatric patients
ith cancer has incalculable benefits to patients, their fami-
ies, and physicians and nurses. While getting relief from pain
or children with cancer may require not just adequate medi-
ation but also considerable patient and family education, the
reatment with analgesic drugs remains the cornerstone of the
herapy [19]. However, information regarding the pharmaco-
ogical treatment of cancer pain in children is lacking. Further
linical trials are needed to evaluate dose equivalence, clin-
cal efficacy and safety of opioid analgesics, differences in
pioid response, adjuvants and other drugs commonly used
o manage opioid-related adverse effects, and dose strengths
ecessary for most children. Unfortunately, the number of
hildren with cancer pain is usually not large enough to
upport well controlled clinical trials at a single institution.
onsequently, multicentre and perhaps multinational efforts
re necessary to fully evaluate analgesic strategies for chil-
ren with cancer pain.
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